Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: Retrospective-observational analytical study

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Shokouh, Taghipour Zahir ^a   Ezatollah, Aalipour ^b   Barand, Poorya ^b   Yang, Feng ^c  

^a Shahid Sadoughi Hospital   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SIZE; CARCINOMA IN SITU; COLLOID CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MUTATION RATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84942446769     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001359     Document Type: Article

References (31)

1. American Cancer Society [2015], Breast Cancer, Key Statistic for Breast Cancer. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
2. Cancer Research UK [2012], Breast Cancer Statistics. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
3. Taghavi A, Fazeli Z, Vahedi M, et al. Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev. 2012; 13: 367-370.
4. Moutafoff C, Coutant C, Bézu C, et al. Prognostic and predictive factors in multifocal breast carcinoma. Gynecol Obstet Fertil. 2011; 39: 425-432.
5. Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005; 11: 278-280.
6. Mahmood H, Faheem M, Mahmood S, et al. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan. Asian Pac J Cancer Prev. 2015; 16: 1019-1024.
7. Baulies S, Cusidó M, González-Cao M, et al. Hormone receptor and HER2 status: the only predictive factors of response to neoadjuvant chemotherapy in breast cancer. J Obstet Gynaecol. 2014: 1-5[Epub ahead of print].
8. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015; 1856: 73-85 doi: 10.1016/j.bbcan.2015.06.002. [Epub ahead of print].
9. Robinson D, Holmberg L, Moller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer. 2008; 99: 611-615.
10. Glover JA, Bannon FJ, Hughes CM, et al. Increased diagnosis and detection rates of carcinoma in situ of the breast. Breast Cancer Res Treat. 2012; 133: 779-784 doi: 10.1007/s10549-012-1975-y.
11. Khokhar A. Breast cancer in India: where do we stand and where do we go? Asian Pac J Cancer Prev. 2012; 13: 4861-4866.
12. Akbar M, Akbar K, Naveed D. Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features. J Ayub Med Coll Abbottabad. 2014; 26: 290-293.
13. Salmen J, Neugebauer J, Fasching PA, et al. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat. 2014; 148: 143-151.
14. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004; 96: 906-920.
15. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005; 93: 1046-1052.
16. Bae SY, Choi M-Y, Cho DH, et al. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 2011; 14: 308-313.
17. Liao GS, Chou YC, Hsu HM, et al. The prognostic value of lymph node status among breast cancer subtypes. Am J Surg. 2015; 209: 717-724.
18. Huober J, Gelber S, Goldhirsch A, et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012; 23: 2843-2851.
19. Han K, Nofech-Mozes S, Narod S, et al. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol). 2012; 24: 183-189.
20. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002; 15: 1318-1325.
21. Seo BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol. 2006; 13: 1211-1218.
22. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002; 117: 916-921.
23. Soerjomataram I, Louwman MWJ, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008; 107: 309-330.
24. Rakha EA, El-Sayed ME, Menon S, et al. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2008; 111: 121-127.
25. Zhang J, Wang Y, Yin Q, et al. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013; 6: 1380-1391.
26. Wang B, Wang X, Wang J, et al. Expression of Ki67 and clinicopathological features in breast cancer. Zhonghua Zhong Liu Za Zhi. 2014; 36: 273-275.
27. Vasseur F, Baranzelli MC, Fournier C, et al. Ki67 in young patients with breast cancer. Gynecol Obstet Fertil. 2013; 41: 16-19.
28. Kim HW, Lee HM, Hwang SH, et al. Patterns and biologic features of p53 mutation types in Korean breast cancer patients. J Breast Cancer. 2014; 17: 1-7.
29. Feeley LP, Mulligan AM, Pinnaduwage D, et al. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2014; 27: 554-561.
30. Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014; 16: R65.
31. Weigelt B1, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological. J Pathol. 2008; 216: 141-150.